bimagrumab   Click here for help

GtoPdb Ligand ID: 8086

Synonyms: BYM-338 | BYM338
Compound class: Antibody
Comment: Bimagrumab is an investigational monoclonal antibody designed to treat the pathological muscle loss and weakness caused by the inflammatory muscle depleting disease, sporadic inclusion body myositis (sIBM).
Click here for help
1. Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ et al.. (2014)
Treatment of sporadic inclusion body myositis with bimagrumab.
Neurology, 83 (24): 2239-46. [PMID:25381300]
2. Berger C, Herrmann T, Lu C, Sheppard K-A, Trifilieff E, Urlinger S. (2013)
Compositions and methods for increasing muscle growth.
Patent number: US8388968. Assignee: Novartis Ag. Priority date: 27/04/2009. Publication date: 05/03/2013.
3. Bogdanovich S, McNally EM, Khurana TS. (2008)
Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C.
Muscle Nerve, 37 (3): 308-16. [PMID:18041051]
4. Han HQ, Zhou X, Mitch WE, Goldberg AL. (2013)
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Int J Biochem Cell Biol, 45 (10): 2333-47. [PMID:23721881]